Indivior (INDV, Financial) has announced its financial results for the first quarter, revealing revenues of $266 million. This figure exceeds analysts' expectations, which had predicted earnings around $243.37 million. The company's performance aligns with its strategic forecasts and is in line with the fiscal year 2025 outlook.
Mark Crossley, CEO of Indivior, expressed satisfaction with the results, indicating that the performance was anticipated as per the company's planning strategies. The financial outcomes underscore Indivior's resilience and its commitment to meeting investor expectations in the evolving market landscape.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Indivior PLC (INDV, Financial) is $14.67 with a high estimate of $16.00 and a low estimate of $13.00. The average target implies an upside of 55.20% from the current price of $9.45. More detailed estimate data can be found on the Indivior PLC (INDV) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Indivior PLC's (INDV, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Indivior PLC (INDV, Financial) in one year is $18.62, suggesting a upside of 97.04% from the current price of $9.45. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Indivior PLC (INDV) Summary page.
INDV Key Business Developments
Release Date: February 20, 2025
- Fourth Quarter Net Revenue: $298 million, up 2% from last year.
- Fourth Quarter SUBLOCADE Net Revenue: $194 million, increased 10% year-over-year.
- Full Year 2024 SUBLOCADE Net Revenue: $756 million, up 20% year-over-year.
- Full Year 2024 Net Revenue: Increased 9%, driven by SUBLOCADE.
- Adjusted Gross Margin for Fourth Quarter: 83%.
- Adjusted Operating Profit for Full Year 2024: Grew by 16% to $312 million.
- Cash and Investments at End of 2024: $347 million.
- Cost Reductions: Over $100 million on an annual basis.
- 2025 Net Revenue Guidance: $955 million to $1,025 million.
- 2025 SUBLOCADE Net Revenue Guidance: $725 million to $765 million.
- 2025 SG&A Expense Guidance: $525 million to $535 million.
- 2025 R&D Expense Guidance: $85 million to $90 million.
- 2025 Adjusted Operating Profit Guidance: $185 million to $225 million.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Indivior PLC (INDV, Financial) achieved a 20% net revenue growth for its primary product, SUBLOCADE, in 2024.
- The company implemented cost reductions of over $100 million annually, contributing to more than $50 million in savings.
- Indivior PLC (INDV) resolved certain legacy litigation, reducing enterprise risk and enhancing financial flexibility.
- The company is optimistic about FDA approval for label changes to SUBLOCADE, which could improve its competitive positioning.
- Indivior PLC (INDV) is investing in commercial strategies to increase awareness of SUBLOCADE, aiming to expand the market and increase market share.
Negative Points
- Indivior PLC (INDV) faced challenges in 2024, including competition in the US long-acting injectable category and the discontinuation of its schizophrenia treatment, PERSERIS.
- The company expects a sharp decline in net revenue from SUBOXONE Film in 2025 due to intensified competitive generic pricing activity.
- SUBLOCADE's net revenue is anticipated to remain relatively unchanged in 2025 due to competitive dynamics and funding challenges in the justice system.
- Indivior PLC (INDV) projects a decline in total net revenue and adjusted operating profit for 2025 compared to 2024.
- The company is not currently considering business development or a return of capital to shareholders, focusing instead on reinvesting in SUBLOCADE and completing clinical studies.
